WO2004089348A3 - Use of a serotonin transporter inhibitor for the treatment of pulmonary hypertension - Google Patents

Use of a serotonin transporter inhibitor for the treatment of pulmonary hypertension Download PDF

Info

Publication number
WO2004089348A3
WO2004089348A3 PCT/EP2004/004530 EP2004004530W WO2004089348A3 WO 2004089348 A3 WO2004089348 A3 WO 2004089348A3 EP 2004004530 W EP2004004530 W EP 2004004530W WO 2004089348 A3 WO2004089348 A3 WO 2004089348A3
Authority
WO
WIPO (PCT)
Prior art keywords
pulmonary hypertension
treatment
serotonin transporter
transporter inhibitor
inhibitor
Prior art date
Application number
PCT/EP2004/004530
Other languages
French (fr)
Other versions
WO2004089348A2 (en
Inventor
Serge Adnot
Saadia Eddahibi
Original Assignee
Assist Publ Hopitaux De Paris
Inst Nat Sante Rech Med
Serge Adnot
Saadia Eddahibi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assist Publ Hopitaux De Paris, Inst Nat Sante Rech Med, Serge Adnot, Saadia Eddahibi filed Critical Assist Publ Hopitaux De Paris
Publication of WO2004089348A2 publication Critical patent/WO2004089348A2/en
Publication of WO2004089348A3 publication Critical patent/WO2004089348A3/en
Priority to US11/246,282 priority Critical patent/US8614247B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to a method for preventing, attenuating or treating pulmonary hypertension in an individual in need thereof, comprising administering at least one 5-HTT inhibitor to said individual.
PCT/EP2004/004530 2003-04-10 2004-04-09 Use of a serotonin transporter inhibitor for the treatment of pulmonary hypertension WO2004089348A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/246,282 US8614247B2 (en) 2003-04-10 2005-10-11 Methods for preventing, attenuating or treating pulmonary hypertension using a serotonin transporter inhibitor, and pharmaceutical compositions for the treatment thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46142703P 2003-04-10 2003-04-10
US60/461,427 2003-04-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/246,282 Continuation US8614247B2 (en) 2003-04-10 2005-10-11 Methods for preventing, attenuating or treating pulmonary hypertension using a serotonin transporter inhibitor, and pharmaceutical compositions for the treatment thereof

Publications (2)

Publication Number Publication Date
WO2004089348A2 WO2004089348A2 (en) 2004-10-21
WO2004089348A3 true WO2004089348A3 (en) 2005-04-07

Family

ID=33159825

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/004530 WO2004089348A2 (en) 2003-04-10 2004-04-09 Use of a serotonin transporter inhibitor for the treatment of pulmonary hypertension

Country Status (1)

Country Link
WO (1) WO2004089348A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007077457A2 (en) * 2006-01-06 2007-07-12 The Royal Veterinary College Treatment of equine laminitis with 5-ht1b/ 1d antagonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000056312A1 (en) * 1999-03-19 2000-09-28 Knoll Gmbh Treatment of pulmonary hypertension

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000056312A1 (en) * 1999-03-19 2000-09-28 Knoll Gmbh Treatment of pulmonary hypertension

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DAWSON, L. A. ET AL: "The role of 5-HT1A and 5-HT1B/1D receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: the mechanism of action of (.+-.)pindolol", NEUROPHARMACOLOGY , 39(6), 1044-1052 CODEN: NEPHBW; ISSN: 0028-3908, 2000, XP001199433 *
EDDAHIBI S ET AL: "Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene", JOURNAL OF CLINICAL INVESTIGATION, vol. 105, no. 11, June 2000 (2000-06-01), pages 1555 - 1562, XP001197383, ISSN: 0021-9738 *
EDDAHIBI S ET AL: "Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cells: Relationship with mitogenic action of serotonin", CIRCULATION RESEARCH, vol. 84, no. 3, 19 February 1999 (1999-02-19), pages 329 - 336, XP001197384, ISSN: 0009-7330 *
EDDAHIBI SAADIA ET AL: "Dexfenfluramine-associated changes in 5-hydroxytryptamine transporter expression and development of hypoxic pulmonary hypertension in rats", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 297, no. 1, April 2001 (2001-04-01), pages 148 - 154, XP001197387, ISSN: 0022-3565 *
EDDAHIBI SAADIA ET AL: "Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension", JOURNAL OF CLINICAL INVESTIGATION, vol. 108, no. 8, October 2001 (2001-10-01), pages 1141 - 1150, XP001197388, ISSN: 0021-9738 *
HICKS M N ET AL: "Reply to Lechin et al.", BRITISH JOURNAL OF PHARMACOLOGY, vol. 137, no. 6, November 2002 (2002-11-01), pages 938, XP001199428, ISSN: 0007-1188 *
KEEGAN A ET AL: "Contribution of the 5-HT1B receptor to hypoxia-induced pulmonary hypertension - Converging evidence using 5-HT1B-receptor knockout mice and the 5-HT1B/1D-receptor antagonist GR127935", CIRCULATION RESEARCH, (7 DEC 2001) VOL. 89, NO. 12, PP. 1231-1239. PUBLISHER: LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA. ISSN: 0009-7330., 2001, XP001199421 *
MARCOS ELISABETH ET AL: "Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension.", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 168, no. 4, 15 August 2003 (2003-08-15), pages 487 - 493, XP008033559, ISSN: 1073-449X *
TATARCZYNSKA, EWA ET AL: "Effects of combined administration of 5-HT1A and/or 5-HT1B receptor antagonists and paroxetine or fluoxetine in the forced swimming test in rats", POLISH JOURNAL OF PHARMACOLOGY , 54(6), 615-623 CODEN: PJPAE3; ISSN: 1230-6002, 2002, XP008033581 *

Also Published As

Publication number Publication date
WO2004089348A2 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
ZA200502247B (en) Selected CGRP antagonists, method for production and use thereof as medicament.
PT1202724E (en) METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS
WO2004014352A3 (en) Methods for treating carbonic anhydrase mediated disorders
ZA200407813B (en) Medicament for preventing and/or treating chronic rejection.
PL353785A1 (en) Method of treating or inhibiting neurophylic chemotaxis by administering the mek inhibitor
WO2007140002A3 (en) Method for treating non-hodgkin's lymphoma
WO2005084654A3 (en) Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
WO2004073623A3 (en) Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions
PL1651042T3 (en) Herbicidal composition having the herbicidal effect enhanced, and method for enhancing the herbicidal effect
WO2004017948A3 (en) Use of lck inhibitor for treatment of immunologic diseases
WO2005000194A3 (en) Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
EP1596868A4 (en) Method for treating severe heart failure and medicament therefor
WO2007022042A3 (en) Combinations comrising a protein kinase inhibitor being a pyrimidylaminobξnzamide compound and a hsp90 inhibitor such as 17-aag
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
GB0422769D0 (en) Methods for treating deodorizer distillate
WO2003084476A3 (en) Treatment of lung disorder
WO2004080477A8 (en) Aplidine for multiple myeloma treatment
WO2004089348A3 (en) Use of a serotonin transporter inhibitor for the treatment of pulmonary hypertension
WO2007010013A3 (en) Combination comprising a pyrimidylaminobenzamides and a flt-3 inhibitor for treating proliferative diseases
AU2003237088A8 (en) Compounds, compositions and methods for treating or preventing viral infections and associated diseases
AU2003258176A8 (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
AU2003297281A1 (en) Methods for treating, preventing, or reducing cardiac disorders using fadd inhibitors
AU2003230552A1 (en) Methods for treating or inhibiting sick building syndrome, post-lyme disease syndrome, and/or chronic fatigue syndrome
WO2004078142A3 (en) Compositions and methods for preventing and treating endotoxin-related diseases and conditions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11246282

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 11246282

Country of ref document: US

122 Ep: pct application non-entry in european phase